How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?

In the NOVA trial, the PFS benefit for the BRCAwt/HRP patient sub-group was approximately 3 months. Given this small improvement in PFS, prior to the FDA restriction, I always had a risk/benefit discussion with patients reviewing this small benefit and whether the benefit outweighs the risks of trea...

Same as before and not dependent on the agents – so same advice for Olaparib and rucaparib maintenance. Most of the biomarker-negative patients will demonstrate progression on therapy in a relatively short time period but the assessment of HR proficiency by current testing methodology has false posi...